ProciseDx Gets CE Mark for Additional Point-of-Care Drug Monitoring Tests

ProciseDx has earned a CE mark for two new point-of-care tests for the immunosuppressive drugs infliximab and adalimumab for use on its ProciseDx system.

The tests gauge the levels of the drugs present in fingerprick-blood samples, returning results in less than five minutes.

The test data will “allow physicians to make timely dosing decisions and thereby improve drug efficacy,” said ProciseDx CEO Larry Mimms.